US 12,420,100 B2
Implantable medical systems and methods used to detect, characterize or avoid atrial oversensing within an IEGM
Yun Qiao, Sunnyvale, CA (US); Wenwen Li, Studio City, CA (US); Jan Mangual, Rho (IT); and Luke C. McSpadden, Studio City, CA (US)
Assigned to Pacesetter, Inc., Sylmar, CA (US)
Filed by Pacesetter, Inc., Sylmar, CA (US)
Filed on Dec. 14, 2023, as Appl. No. 18/540,679.
Application 18/540,679 is a continuation of application No. 17/171,762, filed on Feb. 9, 2021, granted, now 11,878,174.
Prior Publication US 2024/0115865 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 1/37 (2006.01); A61B 5/283 (2021.01); A61B 5/33 (2021.01); A61N 1/05 (2006.01); A61N 1/368 (2006.01)
CPC A61N 1/3714 (2013.01) [A61B 5/283 (2021.01); A61B 5/33 (2021.01); A61N 1/056 (2013.01); A61N 1/3682 (2013.01); A61N 1/3688 (2013.01)] 25 Claims
OG exemplary drawing
 
1. An implantable medical system configured to selectively perform capture management, the system comprising:
one or more implantable electrodes that can be used for sensing and pacing;
a sensing circuit configured to sense an intracardiac electrogram (IEGM) using at least one of the one or more implantable electrodes;
one or more pulse generators; and
a controller operatively coupled to the sensing circuit and the one or more pulse generators and configured to
cause pacing of a right atrium using at least one of the one or more implantable electrodes configured to be implanted in the right atrium to thereby cause a paced atrial event;
determine whether a portion of the IEGM exceeds a specified sense threshold within a specified window that begins at an end of an atrioventricular delay (AVD) following the paced atrial event;
detect atrial oversensing based on results of the determining whether the portion of the IEGM exceeds the specified sense threshold within the specified window; and
prevent performance of capture management in response to the atrial oversensing being detected.